Merck CEO says cancer vaccine with Moderna will become faster to manufacture

Merck CEO Rob Davis announced on October 14, 2026, that the company expects to shorten the current six-week production timeline for its personalized mRNA cancer vaccine, intismeran autogene, developed with Moderna. The individualized therapy targets tumor-specific mutations and, paired with Keytruda, reduced melanoma recurrence or death by 49% in phase 2 trials while delaying spread in a 1,137-patient phase 3 study. Meanwhile, rival BioNTech reported its mRNA candidate BNT113 missed its progression-free survival endpoint.

Manufacturing turnaround time for cancer vaccine

• ▪Merck CEO Rob Davis stated on October 14, 2026 that he expects the personalized cancer vaccine developed with Moderna to become faster to manufacture over time.
• ▪The personalized cancer vaccine developed by Merck and Moderna currently has a turnaround time of about six weeks from sequencing a patient's tumor to hospital delivery.

How intismeran autogene works with Keytruda

• ▪The cancer vaccine intismeran autogene, developed by Merck and Moderna, is custom-made to target specific mutations in an individual patient's tumor.
• ▪Intismeran autogene trains the immune system to recognize and kill cells carrying specific tumor markers, paired with Merck's immunotherapy Keytruda to enhance the immune attack.

Clinical trial results for Merck and Moderna vaccine

• ▪In a phase 2 melanoma trial, combining intismeran autogene with Keytruda reduced the risk of recurrence or death by 49%.
• ▪Merck and Moderna reported in August 2026 that intismeran autogene delayed recurrence and cancer spread in a phase 3 clinical trial of 1,137 melanoma patients.

Gary Keblish's experience in the clinical trial

• ▪Gary Keblish experienced physical and mental tension from neuropathy during the mRNA cancer vaccine trial, which eventually resolved and left him tumor-free six years after surgery.
• ▪Public school teacher Gary Keblish, diagnosed with high-risk melanoma in 2019, participated in the clinical trial testing Keytruda combined with Merck and Moderna's mRNA cancer vaccine.

Merck opens Advance research facility

• ▪Merck officially opened Advance, a 120,000-square-foot research facility featuring automated robotics and AI, at its West Point, Pennsylvania campus on October 14, 2026.
• ▪Merck opened the Advance facility as part of a strategy to address the upcoming expiration of U.S. compound patents for its top-selling drug Keytruda in December 2028.

BioNTech trial results for cancer vaccine BNT113

• ▪The Independent Data Monitoring Committee recommended continuing BioNTech's BNT113 trial to evaluate overall survival in patients with HPV 16-positive head and neck squamous cell carcinoma.
• ▪BioNTech announced on October 13, 2026 that its experimental mRNA cancer vaccine BNT113 failed to meet its primary endpoint of progression-free survival in a late-stage clinical trial.